Table 2.
Neoadjuvant treatment in borderline resectable pancreatic cancer
| Author, [ref] year | N | Neoadjuvant regimen (%) | No. Resected | R0 resections (%) | Survival |
|---|---|---|---|---|---|
| Christians KK, [35] 2014 | 18 | FOLFIRINOX | 12 (67 %) | 12 (67 %) | Median 22 months |
| Leone F,[36] 2013 | 15 | GEMOX then Gem-RT | 9 (60) | NR | Median 28 months. |
| Takahashi H,[37] 2013 | 80 | Gem-RT | 43 (54) | 42 (98) | 5-y: 34 % |
| Kim E,[38] 2013 | 39 | GEMOX-RT | 24 (62) | NR | Median 18.4 months. |
| Motoi F,[39] 2013 | 16 | Gem-S-1 | NR | NR | 2-y: 31.5 % |
| Kharofa J,[40] 2012 | 12 | FOLFIRINOX then CRT | 7 (58) | 7 (100) | Median not reached at 13 months |
| Lee J,[41] 2012 | 18 | Gem-Cape | 11 (61) | 9 (82) | NR |
| Kang C,[42] 2012 | 32 | Gem +/− Cis-RT | 32 (100) | 28 (88) | NR |
| Chuong M,[43] 2011 | 14 | GTX then CRT | 14 (100) | 12 (86) | NR |
| Barugola G,[44] 2012 | 27 | Various | 27 (100) | NR | NR |
| Stokes J,[45] 2011 | 40 | Cape-RT | 16 (40) | 12 (75) | NR |
| Sahora K,[46] 2011 | 12 | Gem-Tax | 4 (33) | NR | NR |
| Chun Y,[47] 2010 | 74 | Various | 74 (100) | 44 (60) | Median 21 month. |
| McClaine R,[48] 2010 | 29 | Various | 12 (41) | 8 (75) | NR |
| Evans,[49] 2008 | 86 | Gem-RT | 64 (74) | NR | 5-y: 36 % |
| Varadhachary,[50] 2008 | 90 | GEM-Cis then Gem-RT | 52 (57) | NR | Median 31 month. |